ClinVar Miner

Variants in gene KRAS

Minimum submission review status: Collection method:
Minimum conflict level:
Gene type:
ClinVar version:

If a variant has more than one submission, it may be counted in more than one significance column. If this is the case, the total number of variants will be less than the sum of the other cells.

pathogenic likely pathogenic uncertain significance likely benign benign drug response not provided total
53 45 127 80 24 1 15 268

Condition and significance breakdown #

Total conditions: 64
Download table as spreadsheet
Condition pathogenic likely pathogenic uncertain significance likely benign benign drug response not provided total
Noonan syndrome 8 6 49 35 0 0 0 98
not provided 26 10 36 17 8 0 0 84
not specified 2 0 23 28 16 0 3 60
Rasopathy 12 6 16 10 5 0 1 46
Neoplasm of the large intestine 22 4 0 0 0 0 0 26
Non-small cell lung cancer 17 5 0 0 0 0 1 22
Cardio-facio-cutaneous syndrome 1 1 10 5 0 0 0 17
Noonan syndrome 3 8 3 1 1 2 0 1 16
Neoplasm of the thyroid gland 13 2 0 0 0 0 0 15
Cardiofaciocutaneous syndrome 2 7 0 1 0 0 0 0 8
Inborn genetic diseases 4 1 3 0 0 0 0 8
Neoplasm of ovary 6 0 0 0 0 0 1 7
Noonan syndrome; Cardio-facio-cutaneous syndrome 4 3 0 0 0 0 0 7
Acute myeloid leukemia 2 5 0 0 0 0 0 6
Juvenile myelomonocytic leukemia 4 1 0 0 0 0 0 5
Multiple myeloma 1 4 0 0 0 0 0 5
OCULOECTODERMAL SYNDROME, SOMATIC 4 0 0 0 0 0 0 4
RAS-associated autoimmune leukoproliferative disorder 3 0 1 0 0 0 0 4
Lung adenocarcinoma 0 2 0 0 0 0 1 3
Squamous cell lung carcinoma 1 1 1 0 0 0 0 3
Adenocarcinoma of stomach 0 2 0 0 0 0 0 2
Angiosarcoma 0 2 0 0 0 0 0 2
Carcinoma of pancreas 2 0 0 0 0 0 1 2
Cerebral arteriovenous malformation 2 0 0 0 0 0 0 2
Endometrial carcinoma 0 0 0 0 0 0 2 2
Epidermal nevus syndrome 1 1 0 0 0 0 0 2
Gallbladder cancer 2 0 0 0 0 0 0 2
Hepatocellular carcinoma 0 2 0 0 0 0 0 2
Lung carcinoma 1 1 0 0 0 0 1 2
Malignant melanoma of skin 0 2 0 0 0 0 0 2
Neoplasm of stomach 2 0 0 0 0 0 0 2
Nevus sebaceous 2 0 0 0 0 0 0 2
Noonan syndrome 3; RAS-associated autoimmune leukoproliferative disorder; Acute myeloid leukemia; Cardiofaciocutaneous syndrome 2 1 1 0 0 0 0 0 2
Sarcoma 0 0 0 0 0 0 2 2
none provided 1 0 0 0 1 0 0 2
Adenoid cystic carcinoma 1 0 0 0 0 0 0 1
Bladder cancer, transitional cell, somatic 1 0 0 0 0 0 0 1
Breast adenocarcinoma 1 0 0 0 0 0 0 1
Carcinoma of esophagus 0 1 0 0 0 0 0 1
Cardiofaciocutaneous syndrome 1 1 0 0 0 0 0 0 1
Chronic lymphocytic leukemia 0 1 0 0 0 0 0 1
Epidermal nevus 1 0 0 0 0 0 0 1
Familial cancer of breast 0 0 0 0 0 0 1 1
Familial cancer of breast; Hereditary diffuse gastric cancer; Lung carcinoma; Noonan syndrome 3; Epidermal nevus syndrome; Cerebral arteriovenous malformation; Urinary bladder cancer; Carcinoma of pancreas; RAS-associated autoimmune leukoproliferative disorder; Acute myeloid leukemia; Cardiofaciocutaneous syndrome 2 1 0 0 0 0 0 0 1
Gastrointestinal stromal tumor 0 1 0 0 0 0 0 1
Hereditary breast and ovarian cancer syndrome 0 1 0 0 0 0 0 1
Hereditary diffuse gastric cancer 0 0 1 0 0 0 0 1
KRAS-related RASopathy 0 1 0 0 0 0 0 1
Malignant neoplasm of body of uterus 0 1 0 0 0 0 0 1
Medullary thyroid carcinoma 0 1 0 0 0 0 0 1
Non-immune hydrops fetalis 0 1 0 0 0 0 0 1
Noonan syndrome 1 0 0 0 0 0 0 1 1
Noonan syndrome 3; Cardiofaciocutaneous syndrome 2 1 0 0 0 0 0 0 1
Noonan syndrome 3; Epidermal nevus syndrome; RAS-associated autoimmune leukoproliferative disorder; Acute myeloid leukemia; Cardiofaciocutaneous syndrome 2 0 0 1 0 0 0 0 1
Pancreatic adenocarcinoma 0 1 0 0 0 0 0 1
Pilocytic astrocytoma 1 0 0 0 0 0 0 1
Primary familial hypertrophic cardiomyopathy 0 0 1 0 0 0 0 1
Primary low grade serous adenocarcinoma of ovary 1 0 0 0 0 0 0 1
Toriello-Lacassie-Droste syndrome 0 0 1 0 0 0 0 1
Transitional cell carcinoma of the bladder 0 1 0 0 0 0 0 1
Urinary bladder cancer 1 0 0 0 0 0 0 1
Vascular Tumors Including Pyogenic Granuloma 0 1 0 0 0 0 0 1
cetuximab response - Dosage 0 0 0 0 0 1 0 1
panitumumab response - Dosage 0 0 0 0 0 1 0 1

Submitter and significance breakdown #

Total submitters: 57
Download table as spreadsheet
Submitter pathogenic likely pathogenic uncertain significance likely benign benign drug response not provided total
Illumina Clinical Services Laboratory,Illumina 0 0 48 34 1 0 0 83
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine 23 11 11 21 5 0 0 71
GeneDx 21 6 7 14 14 0 0 62
Invitae 11 2 15 12 4 0 0 44
Database of Curated Mutations (DoCM) 23 15 0 0 0 0 4 28
OMIM 25 0 0 0 0 0 0 25
Integrated Genetics/Laboratory Corporation of America 1 2 12 1 8 0 0 24
Department of Pathology and Laboratory Medicine,Sinai Health System 0 0 22 0 0 0 0 22
ClinGen RASopathy Variant Curation Expert Panel 7 1 1 3 3 0 0 15
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics 0 1 5 2 2 0 0 10
Blueprint Genetics 4 4 1 0 0 0 0 9
Baylor Genetics 4 1 2 0 1 0 0 8
Ambry Genetics 4 1 3 0 0 0 0 8
PreventionGenetics, PreventionGenetics 0 0 1 3 3 0 0 7
CeGaT Praxis fuer Humangenetik Tuebingen 5 0 1 1 0 0 0 7
Laboratory of Translational Genomics, National Cancer Institute 0 0 0 0 0 0 6 6
Greenwood Genetic Center Diagnostic Laboratories,Greenwood Genetic Center 2 0 0 0 3 0 0 5
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories 3 0 0 0 1 0 0 4
Service de Génétique Moléculaire,Hôpital Robert Debré 0 2 1 1 0 0 0 4
ITMI 0 0 0 0 0 0 3 3
Xiao lab, Department of Pathology, Memorial Sloan Kettering Cancer Center 1 2 0 0 0 0 0 3
Molecular Diagnostics Lab,Nemours Alfred I. duPont Hospital for Children 1 1 0 0 0 0 0 2
Genome Sciences Centre,British Columbia Cancer Agency 1 1 0 0 0 0 0 2
Yale Center for Mendelian Genomics,Yale University 2 1 0 0 0 0 0 2
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago 1 0 1 0 0 0 0 2
Gharavi Laboratory,Columbia University 1 0 1 0 0 0 0 2
Arin Greene Laboratory,Boston Children's Hospital, Harvard Medical School 2 0 0 0 0 0 0 2
Institute of Medical Sciences, Banaras Hindu University 2 0 0 0 0 0 0 2
Center for Human Genetics, Inc,Center for Human Genetics, Inc 0 0 0 1 0 0 0 1
Mendelics 0 0 0 0 1 0 0 1
Fulgent Genetics,Fulgent Genetics 1 0 0 0 0 0 0 1
ClinVar Staff, National Center for Biotechnology Information (NCBI) 0 0 0 0 0 0 1 1
PharmGKB 0 0 0 0 0 1 0 1
Institute of Human Genetics,Friedrich-Alexander-Universität Erlangen-Nürnberg 1 0 0 0 0 0 0 1
UCLA Clinical Genomics Center, UCLA 1 0 0 0 0 0 0 1
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics 0 0 0 1 0 0 0 1
Baylor-Hopkins Center for Mendelian Genomics,Johns Hopkins University 0 1 0 0 0 0 0 1
Donald Williams Parsons Laboratory,Baylor College of Medicine 0 1 0 0 0 0 0 1
Centre for Mendelian Genomics,University Medical Centre Ljubljana 0 0 1 0 0 0 0 1
NIHR Bioresource Rare Diseases, University of Cambridge 0 1 0 0 0 0 0 1
Undiagnosed Diseases Network,NIH 0 1 0 0 0 0 0 1
Institute of Human Genetics, University of Leipzig Medical Center 1 0 1 0 0 0 0 1
GenomeConnect, ClinGen 0 0 0 0 0 0 1 1
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen 1 0 0 0 0 0 0 1
Laboratory of Medical Genetics, National & Kapodistrian University of Athens 0 1 0 0 0 0 0 1
St. Jude Clinical Genomics Lab, St. Jude Children's Research Hospital 0 0 1 0 0 0 0 1
Genomic Medicine Lab, University of California San Francisco 0 1 0 0 0 0 0 1
Thoracic Oncology Service,Memorial Sloan Kettering Cancer Center 1 0 0 0 0 0 0 1
Laboratory for Clinical Genomics and Advanced Technology,Dartmouth-Hitchcock Medical Center 1 0 0 0 0 0 0 1
Department of Genetics, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine 0 1 0 0 0 0 0 1
Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn 1 0 0 0 0 0 0 1
GenomeConnect - CFC International 0 0 0 0 0 0 1 1
University Health Network,Princess Margaret Cancer Centre 1 0 0 0 0 0 0 1
Faculté Pluridciplinaire Nador,Université Mohamed Premier 0 0 1 0 0 0 0 1
New York Genome Center 0 0 1 0 0 0 0 1
Molecular Oncology Research Center,Barretos Cancer Hospital 0 1 0 0 0 0 0 1
Hematopathology,The University of Texas M.D. Anderson Cancer Center 1 0 0 0 0 0 0 1

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.